Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer
March 21 2022 - 4:01PM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO).
Dr. Philip Perera, who has led the clinical development and medical
affairs activities since the launch of Longboard, has retired as
CMO while remaining with Longboard in an advisory role.
"On behalf of the board, shareholders, and our
employees, I want to thank Phil for his tremendous contributions,"
said Kevin R. Lind, Longboard’s President and Chief Executive
Officer. "His outstanding leadership and deep commitment to the
company enabled us to successfully complete LP352’s Phase 1 MAD
study and initiate our first clinical trial in patients with
developmental and epileptic encephalopathies, while building out
the team as we executed on our strategy to separate from Arena
Pharmaceuticals. I would like to congratulate him on his retirement
and look forward to continuing to access his knowledge of the
Company, our product candidates and the tremendous unmet need for
patients with neurological diseases.
"At the same time, we are fortunate to have
someone with Randall’s skills, vision and operational expertise
join at such a pivotal time in our evolution," continued Mr. Lind.
"With over 30 years of experience across many different areas of
healthcare, specifically with significant clinical development in
CNS therapeutic indications, he will be a true asset to our
leadership team. We look forward to benefitting from his insights
and leadership as we continue advancing our pipeline."
"I am thrilled to join Longboard and look
forward to working closely with Longboard’s talented team as we
advance our promising neurology-focused pipeline," said Dr. Kaye.
"It is a rare opportunity to work on new, potentially
differentiated best-in-class programs with the prospect to
transform the lives of patients living with these challenging
diseases."
Dr. Randall Kaye has over 30 years of experience
in the medical field. Prior to joining Longboard, Dr. Kaye was
Chief Medical Officer of Neurana Pharmaceuticals, a biotechnology
company focused on the treatment of neuromuscular conditions. Prior
to Neurana, he served as Chief Medical Officer of Click
Therapeutics, Inc., a leader in digital healthcare innovation,
where he was involved in the development of software as a
prescription medical treatment for a number of chronic debilitating
conditions. Prior to Click, he served as Chief Scientific Officer
of SSI Strategy Holdings LLC, where he oversaw clinical
development, medical affairs and pharmacovigilance. In conjunction
with his role at SSI Strategy, he served as Chief Medical Officer
of Axsome Therapeutics, Inc. Earlier in his career, Dr. Kaye held
the positions of Chief Medical Officer of Avanir Pharmaceuticals,
Inc., which was acquired by Otsuka Pharmaceutical Co., and Vice
President, Medical Affairs of Scios Inc. and InterMune, Inc. He
also held clinical development and medical affairs positions at
Pfizer Inc. Dr. Kaye earned an M.D., M.P.H. and B.S. at George
Washington University, completed his pediatric training at UMASS
Medical Center and finished his academic training as a postdoctoral
Research Fellow at Harvard Medical School.
About Longboard
Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on developing
novel, transformative medicines for neurological diseases.
Longboard is working to advance a portfolio of centrally acting
product candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-hydroxytryptamine 2c (5-HT2c) receptor superagonist, with
negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes,
in development for the potential treatment of seizures associated
with a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
in development for the potential treatment of multiple neurological
diseases, and LP143, a centrally acting, full cannabinoid type 2
receptor (CB2) agonist, in development for the potential treatment
of central nervous system (CNS) diseases and disorders.
Forward-Looking Statements
Certain statements in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements
about Dr. Kaye’s contributions, Longboard’s clinical and
preclinical programs, ability to develop and deliver medicines,
prospect to transform the lives of patients, and focus. For such
statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements are disclosed
in Longboard’s filings with the Securities and Exchange Commission
(SEC). These forward-looking statements represent Longboard’s
judgment as of the time of this release. Longboard disclaims any
intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3492dc21-09b9-4f02-94d1-12f708cd7a00
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024